Patent intelligence · US
US 9919027
Lipid nanoparticle of polymyxin
Lipid nanoparticle of polymyxin
Patent details — US 9919027
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 20, 2018
- Expiration
- Mar 15, 2038
- Claims
- 22
- CPC classes
- A61K, A61K38/12, A61K9/0073, A61K9/5123
Quick answer
US 9919027 (Lipid nanoparticle of polymyxin) is held by UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA. Status: granted. Granted Mar 20, 2018. Expires Mar 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K38/12, A61K9/0073, A61K9/5123
More from UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA
Related pharmaceutical patents in our USPTO index.
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11964047
Ophthalmic formulations and related methods
granted -
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
granted -
US 11813278
Highly active compounds against COVID-19
granted
Frequently asked questions
What is US patent 9919027?
US 9919027 (Lipid nanoparticle of polymyxin) is held by UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA. Status: granted. Granted Mar 20, 2018. Expires Mar 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9919027?
UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 9919027 expire?
Our index shows an expiration date of Mar 15, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.